• Afkhami S, D'Agostino MR, Zhang A, Stacey HD, Marzok A, Kang A, Singh R, Bavananthasivam J, Ye G, Luo X, Wang F, Ang JC, Zganiacz A, Sankar U, Kazhdan N, Koenig JFE, Phelps A, Gameiro SF, Tang S, Jordana M, Wan Y, Mossman KL, Jeyanathan M, Gillgrass A, Medina MFC, Smaill F, Lichty BD, Miller MS, Xing Z. 2022. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 185: 896-915.e819.

  • Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine against experimental human norwalk virus illness. N. Engl. J. Med., 365: 2178-2187.

  • Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinje J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowski A, Baehner F, Goodwin R, Edmonds A, Mendelman PM, Plotkin SA. 2015. Serological correlates of protection against a GII.4 norovirus. Clin. Vaccine Immunol., 22: 923-929.

  • An, X., Martinez-Paniagua, M., Rezvan, A., Sefat, S. R., Fathi, M., Singh, S., Biswas, S., Pourpak, M., Yee, C., Liu, X., Varadarajan, N. 2021. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience, 24: 103037.

  • Bansal GP, Fang H, Tan M, Xia M, Wang L, Jiang X. 2013. Norovirus p particle efficiently elicits innate, humoral and cellular immunity. PLoS One, 8: e63269.

  • Barman TK, Huber VC, Bonin JL, Califano D, Salmon SL, McKenzie ANJ, Metzger DW. 2022. Viral PB1-F2 and Host IFN-γ Guide ILC2 and T Cell Activity during Influenza Virus Infection. Proceedings of the National Academy of Sciences, vol. 119: e2118535119.

  • Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinje J, Gregoricus N, Frenck RW, Jr., Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM. 2015. Norovirus vaccine against experimental human gii.4 virus illness: a challenge study in healthy adults. J. Infect. Dis., 211: 870-878.

  • Bonifait L, Charlebois R, Vimont A, Turgeon N, Veillette M, Longtin Y, Jean J, Duchaine C. 2015. Detection and quantification of airborne norovirus during outbreaks in healthcare facilities. Clin. Infect. Dis., 61: 299-304.

  • Chan MC, Lee N, Hung TN, Kwok K, Cheung K, Tin EK, Lai RW, Nelson EA, Leung TF, Chan PK. 2015. Rapid emergence and predominance of a broadly recognizing and fast-evolving norovirus GII.17 variant in late 2014. Nat. Commun., 6: 10061.

  • Chen J, Li Y, Lai F, Wang Y, Sutter K, Dittmer U, Ye J, Zai W, Liu M, Shen F, Wu M, Hu K, Li B, Lu M, Zhang X, Zhang J, Li J, Chen Q, Yuan Z. 2021. Functional comparison of interferon-α subtypes reveals potent hepatitis b virus suppression by a concerted action of interferon-α and interferon-γ signaling. Hepatology, 73: 486-502.

  • Chhabra P, de Graaf M, Parra GI, Chan MC-W, Green K, Martella V, Wang Q, White PA, Katayama K, Vennema H, Koopmans MPG, Vinje J. 2019. Updated classification of norovirus genogroups and genotypes. J. Gen. Virol., 100: 1393-1406.

  • de Graaf M, van Beek J, Koopmans MP. 2016. Human norovirus transmission and evolution in a changing world. Nat. Rev. Microbiol., 14: 421-433.

  • Dutch RE, Ramani S, Estes MK, Atmar RL. 2016. Correlates of protection against norovirus infection and disease-where are we now, where do we go? PLoS Pathog., 12: e1005334.

  • Guo J, Mondal M, Zhou D. 2018. Development of novel vaccine vectors: chimpanzee adenoviral vectors. Hum. Vaccines Immunother., 14: 1679-1685.

  • Guo L, Wang J, Zhou H, Si H, Wang M, Song J, Han B, Shu Y, Ren L, Qu J, Hung T. 2008. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine, 26: 460-468.

  • Hartwell, B.L., Melo, M.B., Xiao, P., Lemnios, A.A., Li, N., Chang, J.Y.H., Yu, J., Gebre, M.S., Chang, A., Maiorino, L., Carter, C., Moyer, T.J., Dalvie, N.C., Rodriguez-Aponte, S.A., Rodrigues, K.A., Silva, M., Suh, H., Adams, J., Fontenot, J., Love, J.C., Barouch, D.H., Villinger, F., Ruprecht, R.M., Irvine, D.J., 2022. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci Transl Med 14, eabn1413.

  • Hou W, Lv L, Wang Y, Xing M, Guo Y, Xie D, Wei X, Zhang X, Liu H, Ren J, Zhou D. 2022. 6-valent virus-like particle-based vaccine induced potent and sustained immunity against noroviruses in mice. Front. Immunol., 13: 906275.

  • Harkema J. R. 1990. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ. Health Perspect., 85: 231-238.

  • Kendra JA, Tohma K, Parra GI. 2022. Global and regional circulation trends of norovirus genotypes and recombinants, 1995-2019: a comprehensive review of sequences from public databases. Rev. Med. Virol., 32: e2354.

  • Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, Gottlieb K, Trager G, Tucker SN. 2018. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight, 3: e121077.

  • Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, Aerssens A, De Coster I, Borkowski A, Baehner F, Van Damme P. 2018. Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial. J. Infect. Dis., 217: 597-607.

  • Leroux-Roels I, Maes C, Joye J, Jacobs B, Jarczowski F, Diessner A, Janssens Y, Waerlop G, Tamminen K, Heinimaki S, Blazevic V, Leroux-Roels G, Klimyuk V, Adachi H, Hiruta K, Thieme F. 2022. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine. Front. Immunol., 13: 1021500.

  • Li J, Zhang L, Zou W, Yang Z, Zhan J, Cheng J. 2023. Epidemiology and genetic diversity of norovirus GII genogroups among children in Hubei, China, 2017-2019. Virol. Sin., 38: 351-362.

  • Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med., 9: 548-553.

  • Liu J, Xu K, Xing M, Zhuo Y, Guo J, Du M, Wang Q, An Y, Li J, Gao P, Wang Y, He F, Guo Y, Li M, Zhang Y, Zhang L, Gao GF, Dai L, Zhou D. 2021. Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discovery, 7: 123.

  • Liu W, Li H, Liu B, Lv T, Yang C, Chen S, Feng L, Lai L, Duan Z, Chen X, Li P, Guan S, Chen L. 2023. A new vaccination regimen using adenovirus-vectored vaccine confers effective protection against african swine fever virus in swine. Emerg. Microb. Infect., 12: 2233643.

  • Ma, Y., Li, J., 2011. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J. Virol., 85: 2942-2952.

  • Mao, T., Israelow, B., Peña-Hernández, M.A., Suberi, A., Zhou, L., Luyten, S., Reschke, M., Dong, H., Homer, R.J., Saltzman, W.M., Iwasaki, A., 2022. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523.

  • Marks PJ, Vipond IB, Carlisle D, Deakin D, Fey RE, Caul EO. 2000. Evidence for airborne transmission of Norwalk-Like Virus (NLV) in a hotel restaurant. Epidemic Infect, 124: 481-487.

  • Mathew LG, Herbst-Kralovetz MM, Mason HS. 2014. Norovirus narita 104 virus-like particles expressed in nicotiana benthamiana induce serum and mucosal immune responses. BioMed Res. Int. 2014:2014:807539.

  • Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhoven W, Truyers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguih M, Ewer K, Angus B, Pollard AJ, Snape MD. 2016. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA, 315: 1610-1623.

  • Moore MD, Goulter RM, Jaykus L-A. 2015. Human norovirus as a foodborne pathogen: challenges and developments. Annu. Rev. Food Sci. Technol., 6: 411-433.

  • Parys A, Vandoorn E, Chiers K, Passvogel K, Fuchs W, Mettenleiter TC, Van Reeth K. 2022. Exploring prime-boost vaccination regimens with different H1N1 swine influenza a virus strains and vaccine platforms. Vaccines, 10: 1826.

  • Pattekar A, Mayer LS, Lau CW, Liu C, Palko O, Bewtra M, Consortium H, Lindesmith LC, Brewer-Jensen PD, Baric RS, Betts MR, Naji A, Wherry EJ, Tomov VT. 2021. Norovirus-specific CD8+ T cell responses in human blood and tissues. Cell Mol Gastroenterol Hepatol, 11: 1267-1289.

  • Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, Atmar RL. 2015. Mucosal and cellular immune responses to Norwalk Virus. JID (J. Infect. Dis.), 212: 397-405.

  • Russell CD, Unger SA, Walton M, Schwarze J. 2017. The human immune response to respiratory syncytial virus infection. Clin. Microbiol. Rev., 30: 481-502.

  • Shanker S, Czako R, Sapparapu G, Alvarado G, Viskovska M, Sankaran B, Atmar RL, Crowe JE, Estes MK, Prasad BVV. 2016. Structural Basis for Norovirus Neutralization by an Hbga Blocking Human Iga Antibody. Proceedings of the National Academy of Sciences, vol. 113: E5830-E5837.

  • Tamminen K, Malm M, Vesikari T, Blazevic V. 2018. Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens. Clin. Immunol., 197: 110-117.

  • Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. 2013. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One, 8: e70409.

  • Tan M, Tian Y, Zhang D, Wang Q, Gao Z. 2024. Aerosol transmission of norovirus. Viruses, 16: 151.

  • Todd, Kyle, Tripp, Ralph. 2019. Human norovirus: experimental models of infection. Viruses, 11: 151.

  • van Beek J, de Graaf M, Al-Hello H, Allen DJ, Ambert-Balay K, Botteldoorn N, Brytting M, Buesa J, Cabrerizo M, Chan M, Cloak F, Bart D, olo I, Guix S, Hewitt J, Iritani N, Jin M, Johne R, Lederer I, Mans J, Martella V, NoroNet. 2018. Molecular surveillance of norovirus, 2005-16: an epidemiological analysis of data collected from the noronet network. Lancet Infect. Dis., 18: 545-553.

  • Verma V, Tan W, Puth S, Cho K-O, Lee SE, Rhee JH. 2016. Norovirus (NOV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB. J. Transl. Med., 14: 135.

  • Wang X, Ku Z, Dai W, Chen T, Ye X, Zhang C, Zhang Y, Liu Q, Jin X, Huang Z. 2015. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Vaccine, 33: 5779-5785.

  • Xing, M., Hu, G., Wang, X., Wang, Y., He, F., Dai, W., Wang, X., Niu, Y., Liu, J., Liu, H., Zhang, X., Xu, J., Cai, Q., Zhou, D., 2024. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines 9, 64.

  • Xing M, Wang Y, Wang X, Liu J, Dai W, Hu G, He F, Zhao Q, Li Y, Sun L, Wang Y, Du S, Dong Z, Pang C, Hu Z, Zhang X, Xu J, Cai Q, Zhou D. 2023. Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants. J. Virol., 97: e0072423.